Moderna Announces First Participant Dosed in Pivotal Phase 3 …
WEB2 days ago · CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun. "Norovirus is a ...
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
WEB2 days ago · CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 ...
Moderna R&D day: $1 billion in cost cuts, 10 product launches
WEBSep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the …
News Details - Moderna
WEBMar 26, 2024 · Moderna announced positive interim results from Phase 3 trial of mRNA-1283, a vaccine that elicits higher immune response and has longer shelf life than Spikevax. The vaccine is part of a combination vaccine against influenza and COVID-19, mRNA-1083, which Moderna plans to bring to market.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBThe updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 …
News Details - Moderna
WEBMar 27, 2024 · Moderna announces positive clinical trial data and program updates for its mRNA pipeline, including respiratory, latent and other vaccine candidates. The Company expects to launch a next-generation COVID-19 vaccine, a flu and COVID-19 combination vaccine, a RSV vaccine and more in 2024.
Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible ...
Moderna says Covid-flu combination vaccine shows positive …
WEBVaccine maker Moderna announced positive late-stage trial results for its Covid-flu combination vaccine. There could be a combined Covid-19 and flu shot in our future, …
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc , opens new tab respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the …
News Details - Moderna
WEBCompany announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022 …